Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seagen Inc. - Common Stock (NQ: SGEN )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Seagen Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Investor Opportunities Ahead of Clinical Updates, Says Analyst Initiating Coverage on Ambrx Biopharma with 'Buy' Rating
B Riley Securities has initiated Ambrx Biopharma Inc (NASDAQ: AMAM) with a Buy rating and a  
Via Benzinga
Seagen's Adcetris/Immunotherapy Combo Achieves 98% Overall Response Rate in Early-Stage Lymphoma Setting
Seagen Inc (NASDAQ: SGEN) announced updated efficacy and safety results from Part C of phase 2 single-arm trial of Adcetris (brentuximab vedotin) combined with nivolumab and standard chemotherapy... 
Via Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $5,800 Today
Via Benzinga
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
$100 Invested In This Stock 20 Years Ago Would Be Worth $4,000 Today
Via Benzinga
Check Out What Whales Are Doing With SGEN
Via Benzinga
(SGEN) - Analyzing Seagen's Short Interest
Via Benzinga
$100 Invested In Seagen 5 Years Ago Would Be Worth This Much Today
Via Benzinga
3 Undervalued Biotech Stocks to Buy Before They Blast Off
Fundamental analysis makes these three undervalued biotech stocks to buy plus they have other catalysts that make them compelling. 
Via InvestorPlace
FTC Wants to Block the Amgen-Horizon Deal: Is Pfizer's Acquisition of Seagen at Risk, Too?
Should Pfizer and Seagen investors be worried? 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Pfizer Just Took Out $31 Billion in Debt. Here's Why That's Good News
The pharmaceutical giant wouldn't be borrowing if it didn't have plans for how to make a tidy return. 
Via The Motley Fool
FDA Signals Support For Pfizer's Maternal RSV Shot Ahead Of Adcomm, Pfizer Raises $31B In Debt To Fund Seagen Deal
Pfizer Inc (NYSE: PFE) plans to raise $31 billion from a debt offering to finance its proposed acquisition of Seagen Inc (NASDAQ: SGEN)  
Via Benzinga
Seagen's Return on Invested Capital Insights
Via Benzinga
FTC Files Lawsuit To Stop Amgen Buying Horizon Therapeutics, Sending Shockwaves Through Biopharma M&A
In a rare move to block a large pharma deal, the U.S. 
Via Benzinga
GDC Stock Alert: Why Is GD Culture Group Up 106% Today?
GD Culture (GDC) stock is rocketing higher on Tuesday with investors reacting to the company's earnings report for Q1 2023. 
Via InvestorPlace
Why Is Guardforce AI (GFAI) Stock Up Today?
Guardforce AI (GFAI) stock is on the rise Tuesday after the AI company announced the closing of a public share offering. 
Via InvestorPlace
GILD Stock Price Predictions: Is Gilead Sciences Really Worth $100?
Gilead Sciences (GILD) stock is a hot topic on Tuesday as a new price target predicts a roughly 28% upside for the shares. 
Via InvestorPlace
Seagen (SGEN) Stock Falls 6% After Director Sells Shares
Seagen (SGEN) stock is slipping on Tuesday after one of the company's directors sold shares worth more than $372,000 on Monday. 
Via InvestorPlace
Horizon Tumbles — Taking Seagen, Prometheus With It — On Reports FTC Could Block Its Amgen Takeover
Reports the FTC could block Amgen's takeover of Horizon reverberated across biotechs on Tuesday, with HZNP stock's crash leading the way. 
Via Investor's Business Daily
Vaccine Sales Are Falling. Should You Still Buy Pfizer?
This is a transition year for Pfizer. 
Via The Motley Fool
7 High-Yield Dividend Stocks to Buy and Hold Forever
A stagnant market can be frustrating, but also a good time to look for high-yield dividend stocks to buy now. 
Via InvestorPlace
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?
Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies. 
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Earnings Scheduled For April 27, 2023
Companies Reporting Before The Bell • Cazoo Gr (NYSE:CZOO) is expected to report earnings for its first quarter. 
Via Benzinga
2 Excellent Dividend Stocks to Buy for Less Than $100
Both companies are steals at current levels. 
Via The Motley Fool
Second Quarter Outlook For Biotech Stocks
Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. 
Via Talk Markets
3 Low P/E Stocks That Will Double in One Year
These are the low-PE stocks to buy and represent companies with strong fundamentals and cash flow potential. 
Via InvestorPlace
Hedge Funds Fall Short: Underperforming Low-Cost S&P 500 ETF By 6% In 2023. Here's Why.
So far, 2023 has not started well for the hedge fund sector, as a common SPDR S&P 500 Trust ETF (ARCA: SPY) fared much better than the Global X Guru Index ETF (ARCA: GURU), a fund that invests in the... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.